When Ethan Bartlow was 16 years old, his father died from cancer. “That hit our family really, really hard,” he says. Bartlow discusses his personal motivation to help MD Anderson in our mission to end cancer, along with a message for anyone facing a cancer diagnosis. To learn more, visit: MDAnderson.org/Soccer. Request an appointment at MD Anderson by calling 1-877-632-6789 or online: My.MDAnderson.org/RequestAppointment
Philanthropy Newsroom
Belfer family’s $20 million donation invigorates neurodegeneration research at MD Anderson
Laurence Belfer, on behalf of Robert Belfer and the Belfer family, today announced a $20 million gift to The University of Texas MD Anderson Cancer Center to strengthen neurodegeneration research through the Belfer Neurodegeneration Consortium (BNDC), a transformative multi-institutional initiative to advance the study and treatment of Alzheimer’s disease. Read more.
HOUSTON ― Cancer survivors and tennis legends Chris Evert and Martina Navratilova participated in a fireside-style chat on Wednesday, May 1, at The University of Texas MD Anderson Cancer Center’s signature event, A Conversation with a Living Legend ®, hosted at the Post Oak Hotel at Uptown Houston. The sold-out event raised more than $1.5 million for cell therapy research at MD Anderson with a ticketed audience of 800+.
Past Living Legend honoree and co-anchor of ABC’s Good Morning America, Robin Roberts, led the onstage interview with Evert and Navratilova, and ABC13 Houston’s Eyewitness News anchor, Gina Gaston, emceed the event.
The evening honored Evert’s and Navratilova’s legacies of resilience and determination both on and off the court. The tennis legends shared how their fierce athletic rivalry led to a close friendship they’ve sustained beyond their careers and during each other’s subsequent cancer diagnoses.
This year’s event chairs included Margot Athon, Kelli Blanton, Maya Fleyhan, Vanessa Gilmore, Amy Lee, Ashley Loeffler, Sonny Messiah-Jiles and Delia Stroud. Honorary chairs included Patsy Fourticq, Joan Schnitzer, Cyvia Wolff and Barbara Hurwitz.
From rivals to friends
Evert and Navratilova entertained the audience with personal anecdotes of their friendship, bringing the audience to tears one moment and laughter the next. The women candidly recalled fond memories of traveling around the world playing tennis together, vacationing in Aspen and supporting one another through their cancer experiences.
Navratilova proudly noted that she was wearing a necklace Evert had given her — and that she would continue wearing it in support of Evert, whose ovarian cancer relapsed in 2023, until she was fully healthy again. Evert said she is slowly but surely regaining her strength, having completed treatment and now undergoing maintenance therapy.
Navratilova encouraged audience members to get mammograms and Evert emphasized how genetic testing for BRCA mutations saved her life. Both women noted the importance of getting second opinions when presented with a cancer diagnosis.
“I’m so proud of what you both did for women in sports, but also with how you have handled everything with such grace,” Roberts said at the end of the interview. “The fact that you used your platform to bring about change — to fill this room and raise money [for cancer research] — says a lot about your character.”
Funds raised to support MD Anderson’s cell therapy research
Funds from A Conversation with a Living Legend® Houston benefit cell therapy research and innovation at MD Anderson. This work is led by Katy Rezvani, M.D., Ph.D., professor of Stem Cell Transplantation and the Sally Cooper Murray Chair in Cancer Research, and Elizabeth Shpall, M.D., professor of Stem Cell Transplantation.
Cell therapies incorporate immune cells from a patient or donor that have been engineered or enhanced so that a patient’s immune system can better detect and eliminate cancer cells. These treatments have brought dramatic results for many patients with blood-based cancers, but not all cancer patients benefit. Leveraging the institution's clinical and research expertise, MD Anderson scientists are developing new cell therapies to overcome current challenges and treat a broader spectrum of cancers, such as breast, lung and pancreatic cancers.
“Much of what the world knows about cancer and cell therapy started right here at MD Anderson, and we will continue to advance cell therapy research so more patients benefit,” Rezvani said. “We are deeply grateful to the event organizers and attendees for supporting this important, life-saving work. Your generosity is truly making a difference in the lives of our patients.”
A Conversation With a Living Legend ®
Since 1990, thousands of donors across the country have joined in support of A Conversation With a Living Legend®. Its live interview concept has honored celebrities, heads of state, sports icons and other legendary figures, while audiences in Atlanta; Dallas/Fort Worth; Houston; Las Vegas; San Antonio; and Washington, D.C., have raised more than $55 million for cancer research and patient care programs to date. Since the first Houston-based event in 2007, the local event series has raised over $14 million.
“The funds raised through this event will have a significant impact on cancer patients and their families in Texas and around the world,” said Peter WT Pisters, M.D., president of MD Anderson. “As MD Anderson stands at a pivotal moment in its history, making transformative impacts on the future of cancer care and research, our supporters’ incredible commitment to our mission continues to inspire us.”
HOUSTON ― Leaders from The University of Texas MD Anderson Cancer Center were presented with more than $2 million from Energy Transfer and Sunoco. The funds, which will support pediatric cancer research at MD Anderson Children’s Cancer Hospital, were raised through the companies’ annual workplace giving campaign.
“We are grateful, year after year, for the unmatched generosity of Energy Transfer and Sunoco,” said Richard Gorlick, M.D., division head and chair of Pediatrics at MD Anderson. “Because of their commitment to our mission to end cancer, patients now and in the future will have access to better, more effective treatments through a new and improved standard of care.”
Since 2014, Energy Transfer and Sunoco employees have led a fundraising effort that has donated more than $15 million to MD Anderson. The annual campaign includes contributions from corporate funds and $1 million from the Energy Transfer/Sunoco Foundation. CAL's Convenience, an independent agent operator of more than 200 Stripes stores at Sunoco gas stations, contributed $65,000 to the effort this year. Every dollar raised will go directly toward MD Anderson’s innovative and lifesaving cancer research and patient programs.
“We are always inspired by the incredible researchers, doctors and nurses within the MD Anderson family,” said Chris Curia, Energy Transfer executive vice president and chief human resources officer. “Their mission, research and treatment efforts are renowned and have had major impacts on millions of patients and their families around the world. It is truly an honor for us to raise money every year to help them further their mission.”
Over the years, funds from Energy Transfer have gone to support numerous research projects, including menin inhibitor research, which is particularly impactful for pediatric patients facing leukemia and other blood diseases.
“Through our research with the menin inhibitor, we are identifying combinations to enhance efficacy and potentially cure more children,” said Branko Cuglievan, M.D., assistant professor of Pediatrics Patient Care at MD Anderson. “With support from Energy Transfer, we are bringing hope to our patients and their families.”
HOUSTON ― The University of Texas MD Anderson Cancer Center today announced a $16.25 million gift from Howard and Susan Elias to accelerate brain tumor and cancer neuroscience research, an emerging field focused on integrating the role of the nervous system in cancer. Howard Elias’ son, Harrison, was diagnosed with brain cancer and underwent successful surgery in 2000. Six years earlier, Howard’s father had died of glioblastoma. These separate diagnoses sparked a giving program over the years, leading to this latest gift which represents the Elias’ continued commitment to MD Anderson’s mission to end cancer and a belief in MD Anderson’s faculty as well as the emerging field of cancer neuroscience.
“Dr. Lang and the incredible team at MD Anderson saved my son’s life more than two decades ago,” said Howard, who has long supported the institution and recently retired as chief customer officer and president of services and digital at Dell Technologies. “Now is the time for us to increase our commitment so we can play a significant role in advancing cancer neuroscience research specifically focused on brain tumors and the nervous system. We want other families to have the chance to see their son grow up, like our family has.”
The Elias’ gift serves as the lead donation to concentrate cross-disciplinary research in cancer neuroscience at MD Anderson. The gift aims to extend patients’ lives and to eliminate their suffering through a comprehensive understanding of the interactions of the nervous system with cancer. Additionally, the Elias family’s generosity and foresight will provide secure, sustainable support for generations of researchers to come as they push the limits in searching for new therapies and cures.
“A future free from cancer is unattainable unless we work together,” said Peter WT Pisters, M.D., president of MD Anderson. “Howard and Susan’s generosity and passion will play a crucial role as we work in this emerging space for generations to come. On behalf of our patients and their families, we extend our heartfelt gratitude.”
Life-saving surgery sparks decades-long philanthropy
Harrison Elias was just shy of 7 years old when he was diagnosed with hypothalamic pilocytic astrocytoma, a form of brain cancer.
“Harrison, his mother and sisters were visiting at his grandparents in Michigan,” said Howard. “They were playing cards and Harrison’s hand flipped around to where his cards were showing. When he said he couldn’t control his hand, we knew immediately something was wrong.”
The initial prognosis the Elias family received was not very promising. They began intensive research and sought multiple opinions around the country. Since they were living in The Woodlands, a suburb of Houston at the time, one of those opinions they sought was from the number one center for cancer care located just across town — MD Anderson.
“We met with Dr. Joann Ater and will never forget her kindness and professionalism,” Howard said. “From there we were connected to Dr. Frederick Lang, who performed the surgery to resect Harrison’s brain tumor a few weeks later. We have stayed in touch with Dr. Lang ever since.”
After the successful surgery, which removed the tumor from the hypothalamus, a deep part of the brain often thought to be inoperable, Harrison spent years building back his physical strength and regaining motor skills that were impacted by the cancer and the treatment. Fortunately, because the tumor was completely removed, Harrison did not need any radiation or chemotherapy. The tumor has not come back after 20+ years.
“Some days I can deadlift 400 pounds but can barely pick up a pencil with my left hand,” says Harrison, who has limited motor function on the left side of his body, a lasting reminder of the brain surgery he underwent as a child. “I have had bad days, actually a lot of bad days, but focusing on the type of person I wanted to be in the future has always gotten me through.”
The future: cancer neuroscience
The nervous system intersects with, and is impacted by, cancer in many ways. This leads to profound and complex consequences for patients, whether pediatric or adult.
“Our focus is on unraveling the fundamental scientific principles driving the cancer-neuroscience interaction,” Lang said. “These advances will drive prevention, early detection and possibly even cures for neurological cancers; will lead to strategies to overcome the adverse effects of cancer treatments on the nervous system; and will address mental health needs in cancer patients, with the ultimate result of dramatically improving outcomes.”
The Cancer Neuroscience Program is a cross-disciplinary program led by Lang, and Vinay Puduvalli, M.D., chair of Neuro-oncology, and Jim Ray, Ph.D., director of the Neurodegeneration Consortium (NDC). Jian Hu, Ph.D., associate professor of Cancer Biology, is the scientific director, and Brittany Parker Kerrigan, Ph.D., is associate director of Research Planning and Development. Future endeavors will encompass brain tumor research, neuroscience and neuro-mental health, as well as the toxic side effects of cancer treatment.
“Our relationship with the Elias’ has grown over the years,” Lang said. “They are committed to the progression of treatments in the neuroscience space. It is incredible to see Harrison thriving more than 20 years later. There can and will be more ‘Harrisons’ thanks to their generosity and foresight.”
HOUSTON ― The University of Texas MD Anderson Cancer Center held its 38th annual Polo on the Prairie on April 27 in West Texas, raising over $1 million for patient care, research and education initiatives. The event drew more than 1,300 attendees to Rancho Verde in Breckenridge, Texas.
“Polo on the Prairie embodies the spirit of West Texans. It is a community dedicated to helping those who have been touched by cancer and the skillful doctors and staff at MD Anderson who care for them,” said Henry Musselman, long-time event host and member of the MD Anderson Cancer Center Board of Visitors (BOV). “We are all a part of Making Cancer History® for MD Anderson’s patients and their loved ones in Texas, across the nation and around the world.”
The event featured a polo tournament, with Midland Polo Club winning the championship. The winning team's players included Jaun “Bauti” Crotto (4 goal), Ulysses Escapite (4 goal), Ulysses Escapite, Jr. (-1 goal) and Molly Smith (0 goal). Following the match, attendees enjoyed a Texas-size chuck wagon barbecue dinner provided by Joe Allen’s Pit Bar-B-Que. Guests also enjoyed a private concert by country music superstars, Big & Rich and Gretchen Wilson, with surprise special guest Cowboy Troy. The evening concluded with fireworks by Pyro Shows of Texas.
“Polo on the Prairie is a testament to the incredible generosity and heartfelt support of our friends in West Texas,” said Darrow Zeidenstein, senior vice president and chief philanthropy officer at MD Anderson. “We are grateful to the Musselmans and the many volunteers who make this event a success, year after year.”
A philanthropic tradition with West Texas roots
Before Polo on the Prairie became a longstanding philanthropic tradition, the late Mary Anne McCloud, of Eastland, and Musselman, her son-in-law, planted the seed of the idea with Charles LeMaistre, M.D., then-president of MD Anderson. McCloud served as a BOV member and wanted to spread awareness in West Texas of the innovative cancer research, care and prevention happening at the nation’s top cancer hospital. She also wished to honor those impacted by cancer and to raise funds to save more lives.
Musselman suggested a polo tournament and began transforming a pasture on the family’s Lazy 3 Ranch into a regulation-sized polo field. The first event was held in 1987, and it has been an annual tradition ever since, with rare exceptions due to weather and COVID-19. This year, Polo on the Prairie found a new home at Rancho Verde, a few miles south of the original polo grounds.
The first Polo on the Prairie raised $25,000. Today, the tournament nets many times that amount and attracts amateur and professional athletes from as far away as Argentina, England and South Africa. To date, Polo on the Prairie has raised more than $11 million for patient care, research and education initiatives at MD Anderson.
“My husband was a patient at MD Anderson, so I know firsthand that MD Anderson saves lives,” said Marci Pearson, a long-time volunteer on the event committee. “Polo on the Prairie contributes to the institution’s ability to do that, and I consider it an honor to be able to participate. I know the money raised for this event is used to benefit the programs and research that help improve and save the lives of many people.”
MD Anderson extends special thanks to this year’s presenting sponsor, ConocoPhillips, and event sponsors Melinda and Henry Musselman, as well as the many sponsors and individuals who have contributed to the success of the event.
HOUSTON ― Howard Meyers, of Dallas, Texas, a member of The University of Texas MD Anderson Cancer Center Board of Visitors (BOV), has committed $25 million to The University of Texas MD Anderson Cancer Center to establish the Meyers Institute for Oncology Nursing. The first of its kind, the Meyers Institute for Oncology Nursing will support and develop nurses throughout their careers by providing educational, professional and wellness-based resources tailored to cancer care nurses and nurse scientists. This generous commitment will be matched through institutional philanthropic efforts, bringing the program funding to its goal of $50 million.
Meyers dedicated the gift in honor of his late wife, Rose-Marie “Rory” Meyers, whose career and legacy as a nurse inspired his philanthropic commitment. As a member of the BOV since 2012, Meyers was also motivated by the institution’s dedication to solving a critical problem: the growing shortage of qualified nurses in cancer care.
“On behalf of the Meyers Foundation, my sons, Craig and Kevin, and I are proud to support MD Anderson by establishing the Meyers Institute for Oncology Nursing in honor of Rory Meyers,” Meyers said. “Rory graduated nursing school in 1962 and was a dedicated nurse who devoted much of her life to providing education for those in the nursing field.”
In addition to addressing the current nursing shortage, the Meyers Institute for Oncology Nursing aims to mitigate nurse burnout and establish a model for other institutions to follow — ultimately helping MD Anderson reach more patients and increase access to its world-leading prevention, diagnostic and treatment services, a key objective of the institution’s Strategy launched in 2021.
“It is critical for us to recruit, retain and upskill nurses who can meet the multifaceted demands of cancer care,” said Peter WT Pisters, M.D., president of MD Anderson. “Howard’s generous gift plays a key role in helping us attract, nurture and keep the best and brightest nurses in health care. The Meyers Institute for Oncology Nursing positions MD Anderson as a game-changer in this landscape by focusing on nursing professionalism, elevating our training and work environments and emphasizing individual career paths for nurses.”
Transforming the future of nursing
The Meyers Institute for Oncology Nursing builds on the existing foundation of MD Anderson’s reputation as a premier institution for nursing. Since 2001, MD Anderson has earned five consecutive Magnet Recognition Program® designations from the American Nurses Credentialing Center, which recognizes health care organizations for superior patient outcomes, teamwork and innovations in professional nursing practice. This designation contributes to MD Anderson’s consistent ranking among the nation’s top hospitals for cancer care in U.S. News & World Report’s “Best Hospitals” survey.
With more than 4,500 registered nurses and the largest clinical trials program in the world, MD Anderson offers a unique, collaborative environment for nurses to lead in the administration of research and management of cancer care. The Meyers Institute for Oncology Nursing will provide new educational and professional opportunities for nurses and nurse scientists to further advance their careers, including A.P.R.N. and R.N. cancer specialty fellowships and residencies.
“Cancer specialty fellowships and residencies enable nurses to learn and refine trailblazing approaches to cancer care that maximize safety and positive outcomes for our patients,” said Rosanna Morris, senior vice president and chief operating officer at MD Anderson. “This advanced level of training elevates our practice and allows MD Anderson to set the nursing gold standard for cancer centers around the world.”
Additionally, the Meyers Institute for Oncology Nursing plans to launch the Nurse Leadership Academy, which will focus on the unique leadership capabilities required to successfully lead within nursing and the support, coaching and mentoring infrastructure required for success.
The Meyers Institute for Oncology Nursing will also feature growth and wellness tracks that offer alternative professional opportunities by prioritizing time spent developing skills or being at home. By dedicating time for professional and personal growth and wellness, the Institute will develop a pipeline of nursing leaders better equipped and positioned to share their perspectives on institutional leadership teams.
“We hope to inspire the next generation of top talent to join cancer care nursing careers,” said Carol Porter, D.N.P., senior vice president and chief nursing officer at MD Anderson. “We want our nurses to be the best at what they do and realize their personal and professional aspirations. Simply put, we want nurses who begin their careers at MD Anderson to retire from MD Anderson.”
HOUSTON ― Vijay Goradia, a Houston-based businessman, philanthropist, and cancer survivor, has donated $10 million to The University of Texas MD Anderson Cancer Center to speed translational research and clinical trials. An initial allocation of $3.5 million will fund the institution’s clinical trial of a CD70-targeted chimeric antigen receptor (CAR) natural killer (NK) cell therapy for patients with renal cell carcinoma (RCC), developed by Katy Rezvani, M.D., Ph.D., professor of Stem Cell Transplantation and Cellular Therapy.
“We are focused on supporting the innovation and commercialization of groundbreaking research,” said Goradia, who also serves as a member of the MD Anderson Cancer Center Board of Visitors’ Executive Committee. “There is so much impactful work happening at MD Anderson. Our first step was to fund Dr. Rezvani’s incredible work in CAR NK cells. She has had some success in treating blood cancers, but now she is working on finding treatments for solid tumors, including renal cancer. We felt this was something worth supporting and we are very excited. We are very hopeful.”
Goradia, a kidney cancer survivor, and his wife, Marie, established the Vijay and Marie Goradia Cancer Fund at MD Anderson through this transformational gift. Their hope is to not only expedite innovation coming from MD Anderson but to invest in the continued success of such research. The remainder of the gift will support additional therapeutics across the research enterprise.
“The generosity of the Goradia family will be felt by cancer patients and their families for decades to come,” said Peter WT Pisters, M.D., president of MD Anderson. “Future translational and therapeutic discoveries that will be supported by this fund, including the CD70 CAR NK trial, will not only expand our efforts in targeting the disease, but also may generate financial benefits to support promising research in the years ahead.”
A true game changer
Renal cell carcinoma is the most common form of kidney cancer. Each year, RCC accounts for approximately 79,000 new cancer cases and 14,000 deaths in the U.S, according to the National Institutes of Health (NIH). While initial treatment with surgery for localized tumors can be curative, about 30% of patients develop metastatic disease, which currently is considered incurable because most of these tumors resist available chemotherapies.
Rezvani has led extensive translational research at MD Anderson to develop and expand the power of NK cells. These tumor-destroying immune cells serve as a first defense against malignancy, but cancer cells can make themselves invisible. By genetically modifying the NK cells with CARs, which are special receptors designed to bind to specific proteins on the surface of cancer cells, the NK cells can better find and eliminate target cancer cells. Rezvani’s laboratory then multiplies the number of CAR NK cells, growing them in large numbers before infusing them into patients.
“This research has the potential to become a viable treatment in a fairly short period of time,” said Rezvani. “I am grateful to Vijay and the entire Goradia family for their support and generosity as well as their belief in the science. This is the right place, the right time, and the right opportunity for such a transformational investment that may have such a grand impact in so many patients’ lives.”
The clinical trial will be a Phase I/II study that will test the safety, feasibility, persistence, and antitumor activity of off-the-shelf cord blood-derived CAR NK cells targeting CD70 and armored with IL-15 for patients with RCC. While this study is directed specifically at RCC, CD70 also is present in other malignancies, including mesothelioma, lung, and bladder cancers, suggesting there may be potential applications in other cancer types.
“MD Anderson has long been a leader in cancer research, diagnosis and treatment and we are inspired by the institution’s efforts to bring cutting-edge research and innovation to patients in need,” said Sapphira Goradia, executive director of the Vijay and Marie Goradia Charitable Foundation. “The Marie and Vijay Goradia Charitable Foundation is dedicated to expanding access to quality health care and we hope this investment will support the acceleration of more effective and affordable cancer treatments.”
Inspiring innovation
Philanthropy has been ingrained in Goradia’s DNA. From his humble beginnings in Mumbai, India, Goradia has made a concerted effort to help others. And he is not stopping anytime soon.
“We are all hoping for the same end result, Making Cancer History®,” he said. “And that cannot happen without meaningful research being done by very smart, talented, committed people. Our hope is that MD Anderson remains at the forefront by attracting very capable and talented people to come and join its already very capable research faculty.”
Goradia said this cannot be accomplished by one, 10 or even 100 philanthropists. It is going to take more.
“We have the format. My hope is that other donors who are interested in funding groundbreaking research and innovation may want to replicate this whole idea,” he said. “We can do this over and over again. Together, let’s end cancer.”
Video Gallery
Previous Stories
2023
Energy Transfer and Sunoco donate more than $2 million to support research at MD Anderson
Howard Meyers establishes Meyers Institute for Oncology Nursing with $25 million gift to MD Anderson
Excitement builds as participants prepare for MD Anderson’s Boot Walk to End Cancer®
Brown Foundation Award for Excellence in Oncology Nursing awarded to Agnes Hsu
MD Anderson Board of Visitors welcomes new members, honors new Life Members
Betty Kim, M.D., Ph.D., honored with Julie and Ben Rogers Award for Excellence
Celebration of Faculty Excellence honors extraordinary clinicians and researchers
MD Anderson announces 2023 class of Andrew Sabin Family Fellows
Howard and Susan Elias make $16.25 million gift to fund cancer neuroscience research at MD Anderson
Polo on the Prairie raises over $1 million for MD Anderson
Cancer survivor gives $10 million to speed translational research and clinical trials
2022
Advanced practice nurse in Leukemia honored with $15,000 cash prize
Andrew Sabin Family Foundation doubles down on commitment to end cancer with $10M gift
Cancer survivors, supporters rally for in-person return of MD Anderson’s Boot Walk to End Cancer®
Timken Foundation advances mission to end cancer with $5 million gift to James P. Allison Institute
IBC Bank's Campaign to End Cancer Tops $2.2 Million
MD Anderson Board of Visitors welcomes new members
Annual awards recognize faculty for excellence in cancer research, clinical care and leadership
MD Anderson announces 2022 class of Andrew Sabin Family Fellows
$15,000 prize recognizes MD Anderson nursing administrator’s commitment to end cancer
H-E-B fundraising campaign raises $175,000
2022 McNair Scholar at MD Anderson Supported by $2.4 Million Gift from The McNair Foundation
McDougall family's $5 million gift brings new hope to those facing brain metastases
MD Anderson's Polo on the Prairie raises more than $1.1 million
2021
Myeloma Research supervisor honored with $15,000 cash prize
MD Anderson’s Boot Walk to End Cancer® raises funds for cancer research and patient programs
MD Anderson welcomes 28 new leaders to Board of Visitors
Kelly Nelson, M.D., honored with Julie and Ben Rogers Award for Excellence
State-wide campaign aims to top add to $5.8 million raised to-date for pediatric cancer programs
Early career researchers demonstrate commitment to innovation, mission to end cancer
Patient & Supporter Stories
From breast cancer patient to chair of MD Anderson’s Boot Walk to End Cancer®
Inflammatory breast cancer survivor finds hope at MD Anderson
Childhood brain tumor diagnosis fuels commitment to future generations
Chief Patient Experience Officer: My pancreatic cancer diagnosis gave me a new perspective
Clinical trial enables marathoner with glioblastoma to keep running
After two melanoma diagnoses, a family reflects on their experiences at MD Anderson
Kidney cancer survivor donates $10 million to advance cellular therapy
Family touched by cancer invests in research and patient wellness initiatives at MD Anderson
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.